TG Therapeutics, Inc.
TGTX
$28.55
$0.592.11%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -1.26% | 9,974.61% | 309.75% | 147.26% | 261.84% |
| Total Depreciation and Amortization | 133.33% | 54.55% | -31.58% | -72.41% | -76.32% |
| Total Amortization of Deferred Charges | -1.69% | -25.27% | -49.42% | -49.13% | -48.55% |
| Total Other Non-Cash Items | 257.76% | -2,391.32% | 81.48% | 83.61% | 33.73% |
| Change in Net Operating Assets | 26.67% | -103.34% | -244.50% | -700.08% | -654.44% |
| Cash from Operations | 176.67% | -89.70% | 34.32% | -249.88% | -94.10% |
| Capital Expenditure | -219.05% | -233.33% | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -198.49% | 598.85% | -323.80% | -39.48% | 135.32% |
| Cash from Investing | -199.05% | 596.71% | -326.18% | -39.75% | 135.28% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 85.61% | -100.00% | 220.00% | 110.00% | -- |
| Repurchase of Common Stock | 100.00% | -3,540.86% | -- | -- | -661,000.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 117.42% | -158.19% | -4,872.59% | -61,120.00% | -607,100.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 131.90% | -148.74% | -140.33% | -173.61% | 72.53% |